Matches in SemOpenAlex for { <https://semopenalex.org/work/W1018875268> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W1018875268 endingPage "20" @default.
- W1018875268 startingPage "13" @default.
- W1018875268 abstract "In a multicenter phase III trial, 267 patients with nonbulky metastatic colorectal cancer who had failed first-line 5-fluorouracil (5-FU) therapy were randomized to receive second-line treatment with either the new topoisomerase agent, irinotecan (Rhône-Poulenc Rorer, Antony, France), or a high-dose infusional 5-FU regimen. Patients treated with irinotecan survived significantly longer than those treated with infusional 5-FU. The 1-year survival rate was 45% for patients receiving irinotecan compared with 32% for patients receiving 5-FU. There also was a significant difference in median progression-free survival (4.2 months v 2.9 months; P = .03) favoring irinotecan. Irinotecan administered at a dose of 350 mg/m2 every 3 weeks was associated with manageable toxicities (the main toxicities were neutropenia and diarrhea). The incidence of these adverse events and of vomiting was higher with irinotecan than with the comparator regimens of infusional 5-FU. However, the incidence of grade 3-4 asthenia was the same in the two treatment arms and mucositis and cutaneous adverse events were more common with 5-FU. Overall, mean global quality of life scores were similar in the two arms of the study throughout the period of treatment and follow-up, demonstrating that the more effective disease control achieved by irinotecan at least maintains quality of life. Indeed, deterioration in quality of life (defined as >50% decrease from baseline score) occurred significantly later in irinotecan-treated patients. In light of these data, irinotecan should be considered the reference treatment for patients with 5-FU-refractory advanced colorectal cancer." @default.
- W1018875268 created "2016-06-24" @default.
- W1018875268 creator A5065867408 @default.
- W1018875268 creator A5090313922 @default.
- W1018875268 date "1999-02-01" @default.
- W1018875268 modified "2023-09-23" @default.
- W1018875268 title "Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group." @default.
- W1018875268 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10213010" @default.
- W1018875268 hasPublicationYear "1999" @default.
- W1018875268 type Work @default.
- W1018875268 sameAs 1018875268 @default.
- W1018875268 citedByCount "10" @default.
- W1018875268 countsByYear W10188752682012 @default.
- W1018875268 countsByYear W10188752682016 @default.
- W1018875268 crossrefType "journal-article" @default.
- W1018875268 hasAuthorship W1018875268A5065867408 @default.
- W1018875268 hasAuthorship W1018875268A5090313922 @default.
- W1018875268 hasConcept C121608353 @default.
- W1018875268 hasConcept C126322002 @default.
- W1018875268 hasConcept C141071460 @default.
- W1018875268 hasConcept C197934379 @default.
- W1018875268 hasConcept C2776694085 @default.
- W1018875268 hasConcept C2777063308 @default.
- W1018875268 hasConcept C2778496288 @default.
- W1018875268 hasConcept C2780259306 @default.
- W1018875268 hasConcept C2780456651 @default.
- W1018875268 hasConcept C2781413609 @default.
- W1018875268 hasConcept C526805850 @default.
- W1018875268 hasConcept C71924100 @default.
- W1018875268 hasConcept C90924648 @default.
- W1018875268 hasConceptScore W1018875268C121608353 @default.
- W1018875268 hasConceptScore W1018875268C126322002 @default.
- W1018875268 hasConceptScore W1018875268C141071460 @default.
- W1018875268 hasConceptScore W1018875268C197934379 @default.
- W1018875268 hasConceptScore W1018875268C2776694085 @default.
- W1018875268 hasConceptScore W1018875268C2777063308 @default.
- W1018875268 hasConceptScore W1018875268C2778496288 @default.
- W1018875268 hasConceptScore W1018875268C2780259306 @default.
- W1018875268 hasConceptScore W1018875268C2780456651 @default.
- W1018875268 hasConceptScore W1018875268C2781413609 @default.
- W1018875268 hasConceptScore W1018875268C526805850 @default.
- W1018875268 hasConceptScore W1018875268C71924100 @default.
- W1018875268 hasConceptScore W1018875268C90924648 @default.
- W1018875268 hasIssue "1 Suppl 5" @default.
- W1018875268 hasLocation W10188752681 @default.
- W1018875268 hasOpenAccess W1018875268 @default.
- W1018875268 hasPrimaryLocation W10188752681 @default.
- W1018875268 hasRelatedWork W1821252775 @default.
- W1018875268 hasRelatedWork W1981265379 @default.
- W1018875268 hasRelatedWork W1981535315 @default.
- W1018875268 hasRelatedWork W1984619574 @default.
- W1018875268 hasRelatedWork W2029367937 @default.
- W1018875268 hasRelatedWork W2034767473 @default.
- W1018875268 hasRelatedWork W2146230542 @default.
- W1018875268 hasRelatedWork W2366073977 @default.
- W1018875268 hasRelatedWork W2410847079 @default.
- W1018875268 hasRelatedWork W3158211927 @default.
- W1018875268 hasVolume "26" @default.
- W1018875268 isParatext "false" @default.
- W1018875268 isRetracted "false" @default.
- W1018875268 magId "1018875268" @default.
- W1018875268 workType "article" @default.